2. >>Policy & Regulation

AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact

US Draft Drug Legislation Could Complicate Market Entry For Generics And Biosimilars

 
• By Chloe Kent

The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.

Senator Joe Manchin is confronted by climate activists leaving his boat on his way to Capitol Hill
Build Back Better crumbled last year after Joe Manchin refused to vote for the legislation • Source: Shutterstock

The US Association for Accessible Medicines has spoken out against draft legislation released by the Senate Finance Committee on 6 July, which largely rehashes the key provisions in a package agreed to by congressional Democrats last year, save for a few updates. The AAM has argued that the new bill does not do enough to protect incentives for developing biosimilars or generic drugs.

The Democratic administration initially hoped to include drug price reform as part of its larger Build Back Better bill, which ultimately crumbled last year following senator Joe Manchin’s refusal to vote for the legislation

More from Policy & Regulation

More from Generics Bulletin

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.